Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

926 - Definitive concurrent chemoradiotherapy using S-1 in the treatment of elderly patients with esophageal cancer


08 Oct 2016


Poster Display


Yongshi Jia


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


Y. Jia

Author affiliations

  • Department Of Radiation Oncology, Zhejiang Provincial People’s Hospital, 310000 - Hangzhou/CN


Abstract 926


Definitive concurrent chemoradiotherapy (CCRT) with 5-florouracil (5-FU) and cisplatin (CDDP) are often associated with signifiant incidence of toxicities in elderly patients with esophageal cancer. This reteospective study was aimed at investigating the efficiency and safety of using S-1 as mono and maintenance therapy combined with concurrent radiotherapy (RT) for elderly patients with esophageal cancer.


From January 2009 to December 2010, 68 (aged over 70 years) elderly patients were included. RT was delivered with a daily fraction of 1.8-2.0Gy to a total radiation dose of 54.0-60.0Gy using the three-dimensional conformal technique (3D-CRT). Preplanned concurrent S-1 (80mg/m2/day) was given on Days 1-14, every 3 weeks. After concurrent chemoradiotherapy (CCRT), maintenance S-1 was repeated up to four cycles.


The median age was 76 years (range: 70-88 years), and the clinical stages were stage I (two patients), stage II (24 patients), stage III (28 patients), and stage IV (14 patients). 51 (75.0%) patients finished treatment on schedule and the median cycles of S-1 was five, of which 35 (51.5%) patients achieved complete response. The median follow-up time was 42.7 months, and the median overall survival (OS) and progression-free survival (PFS) time were 25.7 and 21.5 months, respectively. The 1- and 3-year OS and PFS rates were 70.6%, 41.8% and 68.1%, 32.9%, respectively. Grade ≥3 neutropenia and leukopenia were found in 14 and 13 patients, respectively. The most common non-hematologic toxicity was esophagitis including six and one patients with grade 3 and 4.


For elderly patients with esophageal cancer, S-1 as mono and maintenance chemotherapy in combination with RT could improve survival outcomes with tolerable toxicities. More clinical trials (like NCT02716688) are highly warranted to further clarify this issue.

Clinical trial identification

This is a retrospective study, we did not register our study in International Clinical Trials Registry Platform (ICTRP).

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings